Immunogenicity of a pilot inactivated poliovirus vaccine with trypsin-treated type 3-component.
A modified trivalent enhanced potency IPV (E-IPV) containing trypsin-treated PV3/Saukett as the type 3-component (TryIPV) was evaluated in preclinical and Phase I and Phase II clinical trials with the regular E-IPV as a control. In Balb/c mice, TryIPV-induced antibodies targeted outside the trypsin-sensitive antigenic site, as expected. Immunogenicity of TryIPV in man, as judged by a booster response in neutralizing antibodies to type 1, 2 or 3 poliovirus, was as good as that of the regular E-IPV in both adults and children. In children the preimmunization titres of antibodies neutralizing the trypsin-treated PV3/Saukett were significantly lower than those for the untreated virus. Both vaccines induced a striking increase of antibody titres to both virus preparations. No significant harmful effects were observed. We conclude that the pilot vaccine is suitable for further evaluation.
Piirainen
L
L
Enterovirus Laboratory, National Public Health Institute, Helsinki, Finland.
Roivainen
M
M
Litmanen
L
L
Eskola
J
J
Beuvery
E C
EC
Hovi
T
T
D000328:Adult; D000818:Animals; D002675:Child, Preschool; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D010865:Pilot Projects; D017955:Poliovirus / Q000187:drug effects / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000009:adverse effects / Q000276:immunology*; D014357:Trypsin; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology
D011054:Poliovirus Vaccine, Inactivated; D015164:Vaccines, Inactivated; D014357:Trypsin